A 2010 Cochrane analysis found that pirfenidone significantly improved progression-free survival.

Rates of progression-free survival were also similar in both groups.

Another report found a similar 5-year survival at about 65% with 51% progression-free survival.

Of them, 9 patients on APG01 and none on radiation alone achieved 6-months progression-free survival.

No statistically significant differences in time-to-subjective progression or in progression-free survival were seen.

These studies also showed that progression-free survival improved by less than three months, and that there was a high rate of side effects.

The small increase in "progression-free survival" reflects a small, temporary effect in slowing tumor growth.

The progression-free survival for differentiated thyroid cancer patients was 84 weeks.

This study was powered to accept as much as a 50% increase in progression-free survival as being noninferior.

Ellagic acid supplementation did not improve overall or progression-free survival of patients with prostate cancer in this trial.